Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8052W HIGH $3.06
Volume
10.53 K
Value Traded
72.87 K
Short % Float
3.13%
-0.74%Week
-1.22%1 Month
-7.11%3 Month
-23%6 Month
-98.04%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
21.73 M
EPS (TTM)
-1.33
P/E Ratio
-
Ent. Value
6.38 M
Total Shares
10.73 M
Float Shares
9.96 M
Insiders
8.36%
Institutions
35.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AYTU Catalyst Timeline
Dated clinical, regulatory and corporate events for Aytu BioPharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aytu BioPharma, Inc.
306Total events
2Upcoming
77Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
Aytu reports fiscal 2026 full year and Q4 operational and financial results
◆Oral PresentationPresentation
Fireside Q&A at Planet MicroCap Las Vegas 2026 Investor Conference
◆Quarterly UpdateCorporate
Report fiscal 2026 second quarter operational and financial results
▲Product LaunchEXXUAApprovedPost-Market
Nationwide commercial launch of EXXUA
major depressive disordersource ↗
▲FDA ApprovalEXXUAApprovedFDA Decision
FDA approval of EXXUA for MDD
major depressive disordersource ↗
●Oral PresentationEXXUAApprovedPresentation
Investor Day presentations on EXXUA
major depressive disordersource ↗
◆R&D DayPresentation
Aytu BioPharma to participate in Lytham Partners 2026 Investor Healthcare Summit
▲Product LaunchEXXUAApprovedPost-Market
EXXUA formally launched following sales force training
major depressive disordersource ↗
▲Product LaunchEXXUAApprovedPost-Market
Initial commercial availability of EXXUA
major depressive disordersource ↗
▲Product LaunchEXXUAApprovedPost-Market
EXXUA made commercially available
major depressive disordersource ↗
▲Partnership / LicenseEXXUAApprovedCorporate
Exclusive agreement to commercialize EXXUA in the United States
major depressive disordersource ↗
▲Manufacturing MilestoneCMC / Inspection
Enhanced margin improvement in ADHD products expected beginning in calendar 2024
◆Timing GuidancePresentation
Expected FDA approval of Cotempla XR-ODT site transfer PAS
attention deficit hyperactivity disorder (ADHD)source ↗
◆Manufacturing MilestoneCMC / Inspection
Expect to begin outsourced manufacturing of Adzenys and Cotempla
attention deficit hyperactivity disorder (ADHD)source ↗
◆Manufacturing MilestoneCMC / Inspection
Expect to begin outsourced manufacturing of Adzenys and Cotempla
attention deficit hyperactivity disorder (ADHD)source ↗
▲Timing GuidancePresentation
Expected margin improvement from manufacturing transfer in calendar 2024
▲Manufacturing MilestoneCMC / Inspection
Initial ramp-up of contract manufacturing for Adzenys XR-ODT and Cotempla XR-ODT
ADHDsource ↗
▲Manufacturing MilestoneCMC / Inspection
Initial ramp-up of contract manufacturing for Adzenys XR-ODT and Cotempla XR-ODT
ADHDsource ↗
▲Manufacturing MilestoneCMC / Inspection
FDA approval of Cotempla XR-ODT Prior Approval Supplement for manufacturing site transfer
attention deficit hyperactivity disorder (ADHD)source ↗
◆Reverse Stock SplitCorporate
Potential reverse stock split to be enacted before October 4, 2023
●Manufacturing MilestoneCMC / Inspection
Initial ramp-up of contract manufacturing of Adzenys XR-ODT expected in late calendar 2023
attention deficit hyperactivity disorder (ADHD)source ↗
●Manufacturing MilestoneCMC / Inspection
Initial ramp-up of contract manufacturing of Cotempla XR-ODT expected in late calendar 2023
attention deficit hyperactivity disorder (ADHD)source ↗
▲FDA ApprovalFDA Decision
FDA approval of Cotempla XR-ODT PAS for manufacturing site transfer
ADHDsource ↗
▲Timing GuidancePresentation
Expected FDA approval of Cotempla XR-ODT site transfer PAS
attention deficit hyperactivity disorder (ADHD)source ↗
▲Partnership / LicenseCorporate
Exclusive agreement with Medomie Pharma to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority
ADHDsource ↗
●sNDA SubmissionRegulatory Filing
Submitted Cotempla XR-ODT manufacturing site transfer Prior Approval Supplement to FDA
attention deficit hyperactivity disorder (ADHD)source ↗
▲Manufacturing MilestoneCMC / Inspection
FDA approval of Adzenys XR-ODT site transfer PAS previously announced
attention deficit hyperactivity disorder (ADHD)source ↗
●sNDA SubmissionRegulatory Filing
Cotempla XR-ODT Prior Approval Supplement submitted to FDA
ADHDsource ↗
▲Manufacturing MilestoneCMC / Inspection
FDA approval of Adzenys XR-ODT Prior Approval Supplement for manufacturing site transfer
attention deficit hyperactivity disorder (ADHD)source ↗
▲Trial CompletionTrial
Cotempla XR-ODT bioequivalence study successfully completed
attention deficit hyperactivity disorder (ADHD)source ↗
▲Manufacturing MilestoneCMC / Inspection
FDA approval of Adzenys XR-ODT Prior Approval Supplement for manufacturing site transfer
attention deficit hyperactivity disorder (ADHD)source ↗
●Timing GuidancePresentation
Expected submission of Cotempla XR-ODT site transfer PAS to FDA
attention deficit hyperactivity disorder (ADHD)source ↗
▼Program DiscontinuationCorporate
Suspended pipeline program (likely AR101/Healight) expenses incurred
Past FDA Catalysts and PDUFA Decisions
How AYTU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2017-09-15 | Adzenys Er (amphetamine) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
$58M
Commercial Value
Undervalued
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 84%
Micro Cap(rank 555 of 660)
Percentile Rank
Aytu BioPharma, Inc. faces pipeline headwinds (24/100), with 1 assets in development.
Commercial products (revenue basis: latest annual revenue in its 10-K, to Jun 2026; product lines from the latest annual filing) Revenue $57.6M x 1.0 = $58M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ADHD Portfolio | $46M | $58M | -20.4% |
| EXXUA | $7M | - | - |
| Pediatric Portfolio | $5M | $9M | -41.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NT0102 Small moleculeMarketedNCT01835548 | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | COMPLETED | 87 | Jul 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every AYTU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Healight | Ventilator-Associated Pneumonia | Preclinical | 2022-04-25 | 46% reduction in multidrug-resistant Pseudomonas aeruginosa (PA C1-17) versus controls following two separate 20-minute treatmentsRead More | Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Disbrow JarrettOfficer (Chief Business Officer) | Buy | 16,666 29,462 held | $1.50 | 06/09/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in AYTU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AYTU for Q2 2026. | ||||
AYTU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AYTU ranks across every disease it competes in
Competitive Position is a premium feature
See how AYTU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAYTU News
AYTUAytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Aytu BioPharma reported a 6.4% increase in net revenue for Q4 2026, totaling $16.1 million. The launch of EXXUA has shown promising results, with significant growth in prescriptions and revenue. However, the overall revenue for the fiscal year decreased compared to the previous year, and the company continues to invest in commercialization efforts. Despite a net loss for the year, Aytu remains optimistic about future growth prospects.
Read more →AYTUAytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Aytu BioPharma will announce its fiscal 2026 full year and fourth quarter results on September 22, 2026. The company will hold a conference call and webcast at 4:30 p.m. Eastern time to discuss these results. Interested parties can join the call using provided dial-in information, and a replay will be available until October 6, 2026.
Read more →AYTUAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Aytu BioPharma will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026. The company will participate in a Fireside Q&A session and conduct one-on-one investor meetings. This event highlights Aytu's commitment to engaging with investors and promoting its innovative medicines for CNS diseases.
Read more →AYTU▼ -10.3%on this news
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Aytu BioPharma reported its fiscal 2026 second quarter results, highlighting a net revenue of $15.2 million and a net loss of $10.6 million. The company successfully launched EXXUA, a new treatment for major depressive disorder, in December 2025, with initial positive indicators from prescriber engagement. Despite challenges, including a decrease in revenue from other product portfolios, Aytu maintains a strong cash position to support its growth strategy.
Read more →AYTUAytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma will report its operational and financial results for the second quarter of fiscal 2026 on February 3, 2026. The company has scheduled a conference call and webcast for the same day to discuss these results. Interested parties can access the call through provided dial-in information and a webcast link.
Read more →AYTUAytu BioPharma Recaps Investor Day Held on January 20, 2026
Aytu BioPharma held its Investor Day on January 20, 2026, focusing on the launch of EXXUA, the first FDA-approved 5HT1A agonist for major depressive disorder. Key opinion leaders and Aytu's management presented insights on the drug's clinical importance, commercialization strategy, and early positive feedback. The company plans to provide ongoing updates to investors.
Read more →AYTUAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Aytu BioPharma has launched EXXUA, the first selective 5-HT1A agonist approved for treating major depressive disorder in adults. This new treatment aims to reduce common side effects like sexual dysfunction and weight gain, which often lead to treatment discontinuation. The company emphasizes the importance of addressing both emotional and physical health in managing depression.
Read more →AYTUAytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Aytu BioPharma will participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. CEO Josh Disbrow will be part of a fireside chat moderated by Thomas Flaten from Lake Street Capital Markets. The event will be accessible via webcast, with a replay option available.
Read more →AYTU▲ +10.1%on this news
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue u
Aytu BioPharma announced its financial results for the first quarter of fiscal 2024, highlighting an Adjusted EBITDA of $2.2 million and a net revenue of $22.1 million. Despite the overall revenue decline, the ADHD segment showed significant growth, with a revenue increase of 31% compared to the previous year. The company continues to focus on its Rx segment while planning to wind down the Consumer Health segment, which has seen a substantial drop in revenue. Aytu also reported a current cash balance of $20 million, positioning it for potential growth in the coming quarters.
Read more →AYTU▲ +5.8%on this news
Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla
Aytu BioPharma has received FDA approval for its Prior Approval Supplement (PAS) to transfer manufacturing of Cotempla XR-ODT to a third-party contract manufacturer. This follows a similar approval for Adzenys XR-ODT earlier this year. The company anticipates that the move will not only reduce overhead costs but also lead to enhanced margins for its ADHD product offerings starting in 2024. Aytu is committed to ensuring a smooth transition to the new manufacturing site to meet growing prescription demands for both products.
Read more →AYTU▲ +16.4%on this news· ran to +76% by day 3
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millio
Aytu BioPharma reported its financial results for Q4 2023, achieving record net revenues of $30.7 million and an Adjusted EBITDA of $7.7 million. The Rx segment saw a notable increase in total prescriptions, growing by 32% year-over-year. Despite these successes, the company continues to face challenges, notably in its Consumer Health segment, which contributed negative Adjusted EBITDA. Moving forward, Aytu plans to focus on the Rx segment and monetize or discontinue its Consumer Health operations to enhance profitability.
Read more →AYTUAytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority After the completion of local regulatory approvals, Aytu a
Aytu BioPharma has entered into an exclusive agreement with Medomie Pharma Ltd. to distribute its ADHD medications, Adzenys XR-ODT and Cotempla XR-ODT, in Israel and the Palestinian Authority. The collaboration represents Aytu's first international commercial agreement for these products. Medomie will handle local regulatory approvals and aims to enhance ADHD treatment accessibility in the region.
Read more →AYTU▲ +5.4%on this news
Aytu BioPharma Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administ
Aytu BioPharma has submitted a Prior Approval Supplement (PAS) to the FDA for the manufacturing site transfer of Cotempla XR-ODT. The company anticipates a six-month review process, which, if approved, will allow production to shift to a third-party manufacturer. This move is expected to enhance profitability for Aytu's ADHD products by improving margins by approximately 15%. The transition is expected to begin by late 2023 or early 2024.
Read more →AYTUAytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Cl
Aytu BioPharma has announced a $4 million public offering of its common stock, which is set to close on June 13, 2023. This financing is expected to support the company's strategic shift towards their commercial prescription business and extend the interest-only period on an existing loan until January 2025. Additionally, Abhinav Jain from Nantahala Capital Management will be joining the company's Board of Directors. The company is also suspending its pipeline programs to reduce expenses and maintain financial sustainability.
Read more →AYTUAytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGL
Aytu BioPharma reported financial results for the third quarter of fiscal year 2023, highlighting a notable 32% increase in total prescriptions compared to the same period last year. The company achieved record prescription levels, particularly in its pediatric product line, which saw an 81% revenue increase. However, overall net revenue declined from $24.2 million to $22.7 million, primarily due to challenges in the ADHD segment where net revenue dropped despite a rise in prescriptions. The management remains optimistic about future growth, especially as they adjust their consumer health strategy towards e-commerce sales.
Read more →AYTUAytu BioPharma Subleases a Portion of Its Manufacturing Facility ENGLEWOOD, CO /
Aytu BioPharma has signed an agreement to sublease a portion of its manufacturing facility to AMT Manufacturing Solutions. This sublease, covering over 30% of Aytu's FDA-approved facility, is aimed at improving cost efficiency and reducing operational expenses associated with the company's ADHD product lines. Aytu anticipates that this partnership will boost margins and streamline production processes. The sublease is expected to expand by the end of 2024 to encompass the entirety of the facility, allowing AMTMS to enhance its contract manufacturing services.
Read more →AYTUAytu BioPharma Announces Approval of Adzenys XR-ODT Manufacturing Site Transfer U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 202
Aytu BioPharma has announced FDA approval for the manufacturing site transfer of Adzenys XR-ODT to a third-party manufacturer. This development is expected to increase the product's margins by approximately 15% once the transfer is completed. Additionally, the company has successfully finished a bioequivalence study for Cotempla XR-ODT, with plans to submit its site transfer to the FDA mid-year 2023. Approval of the Cotempla site transfer is anticipated by late 2023 or early 2024.
Read more →AYTUAytu BioPharma Reports Second Quarter of Fiscal Year 2023 Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call T
Aytu BioPharma reported its financial results for Q2 FY2023, marking the second consecutive quarter of positive Adjusted EBITDA. The company's net revenue was $26.3 million, a 14% increase from the same quarter last year, with significant growth in the Rx segment driven by pediatric products. However, there was a net loss of $(6.7) million, influenced by an impairment related to pipeline development. The company continues to focus on transitioning its business strategy towards profitability by suspending costly clinical development programs.
Read more →AYTUAytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results ENGLEWOOD, CO /
Aytu BioPharma has announced a delay in filing its Form 10-Q for the second quarter of fiscal year 2023, which ended on December 31, 2022. This delay is due to additional management review and assessment concerning the accounting for previously issued warrants. The company asserts that this matter will not affect its overall financial results, including assets or revenue. Aytu plans to reschedule its quarterly conference call and file the report as soon as possible.
Read more →AYTU▼ -6.5%on this news
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance ENGLEWOOD, CO /
Aytu BioPharma has successfully regained compliance with Nasdaq's minimum bid price requirement as of January 23, 2023. The company confirmed that its stock maintained a closing bid price of $1.00 or higher for ten consecutive business days. Aytu BioPharma is focused on providing pediatric-focused prescription drugs and consumer health solutions. This compliance is a crucial step for the company in maintaining its listing on the Nasdaq Stock Market.
Read more →About Aytu BioPharma, Inc.
Headquarters7900 E. UNION AVENUE, DENVER, CO, 80237
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next AYTU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime